|
Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia Clinical research trials and Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia. Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia clinical trial. Human subjects often obtain the finest healthcare possible for their Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia
Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia
For Condition: recurrent childhood acute lymphoblastic leukemia
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Children's Cancer Group
Synopsis: RATIONALE: Diagnostic procedures, such as genetic testing, may improve the ability to detect acute lymphocytic leukemia and determine the extent of disease. PURPOSE: Diagnostic study to try to detect changes in the genes of children who have been treated for relapsed acute lymphocytic leukemia.
Details: OBJECTIVES: I. Determine the incidence of p16/p15 homozygous deletions and p15 promoter hypermethylation in acute lymphocytic leukemia cells of children treated on protocol CCG-1941. II. Determine the prognostic importance of p16/p15 abnormalities in these children. III. Determine the presence or absence of p16/p15 abnormalities in the dominant clone at diagnosis if present at relapse in these patients. PROTOCOL OUTLINE: Frozen cells are obtained from samples collected on protocol CCG-1941. DNA is isolated and examined using Southern blot analysis to assay for deletions and promoter hypermethylation of p16 and/or p15. PROJECTED ACCRUAL: Approximately 100 samples will be obtained for this study.
Eligibility:
Study Type: Interventional, Diagnostic
Minimum Age/Maximum Age: /17 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosis of acute lymphocytic leukemia and treated on protocol CCG-1941 - Material cryopreserved in the CCG cell bank --Prior/Concurrent Therapy-- - See Disease Characteristics --Patient Characteristics-- - Age: Children - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
StephenHunger, Study Chair, Children's Cancer Group
Long Beach Memorial Medical Center
Long Beach, California, 90806
United States
Mount Sinai School of Medicine
New York City, New York, 10029
United States
IWK Health Centre
Halifax, Nova Scotia, B3J 3G9
Canada
Herbert Irving Comprehensive Cancer Center
New York City, New York, 10032
United States
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792-6164
United States
Children's Mercy Hospital
Kansas City, Missouri, 64108
United States
British Columbia Children's Hospital
Vancouver, British Columbia, V6H 3V4
Canada
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15213
United States
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Doernbecher Children's Hospital
Portland, Oregon, 97201-3098
United States
Shands Hospital and Clinics, University of Florida
Gainesville, Florida, 32610-100277
United States
Children's Hospital of Denver
Denver, Colorado, 80218
United States
Veterans Affairs Medical Center - Fargo
Fargo, North Dakota, 58102
United States
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
United States
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470
United States
Indiana University Cancer Center
Indianapolis, Indiana, 46202-5289
United States
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4009
United States
CCOP - Merit Care Hospital
Fargo, North Dakota, 58122
United States
CCOP - Kalamazoo
Kalamazoo, Michigan, 49007-3731
United States
Children's Hospital Los Angeles
Los Angeles, California, 90027-0700
United States
Children's Hospital of Columbus
Columbus, Ohio, 43205-2696
United States
University of Nebraska Medical Center
Omaha, Nebraska, 68198-3330
United States
Saint Peter's University Hospital
New Brunswick, New Jersey, 08901-1780
United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232-6838
United States
NYU School of Medicine's Kaplan Comprehensive Cancer Center
New York City, New York, 10016
United States
Children's National Medical Center
Washington D.C., District of Columbia, 20010-2970
United States
Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242-1009
United States
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109-1024
United States
Children's Hospital of Orange County
Orange, California, 92868
United States
David Grant Medical Center
Travis Air Force Base, California, 94535
United States
Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
United States
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
United States
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Children's Hospital and Regional Medical Center - Seattle
Seattle, Washington, 98105
United States
Children's Hospital Medical Center - Cincinnati
Cincinnati, Ohio, 45229-3039
United States
University of Minnesota Cancer Center
Minneapolis, Minnesota, 55455
United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0752
United States
Princess Margaret Hospital for Children
Perth, Western Australia, 6001
Australia
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, 94143-0128
United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
United States
Additional Information:
Study ID Numbers: CDR0000067125; CCG-B9805
Study Start Date: April 1999
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003933
Other Recurrent Childhood Acute Lymphoblastic Leukemia Studies:
1. STI571 in Treating Patients With Recurrent Leukemia
2. Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
3. Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
4. BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
5. Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia
Related Studies:
Other recurrent childhood acute lymphoblastic leukemia Clinical Trials
Other Tennessee Clinical Trials
Other Nashville Clinical Trials
Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia
|
|
|
|
|
|
|
|